超早期伽玛刀立体定向放射外科治疗三叉神经痛(URGEnt-TN):单中心、两臂平行组、实用性、非劣效性、II期随机对照试验的研究方案,采用意向性治疗分析,针对经典或特发性三叉神经痛的难治前伽玛刀立体定向放射外科
三叉神经痛一线治疗为卡马西平,超过50%患者药物治疗失败,早期手术可能改善长期预后,但确诊后、药物难治前的超早期伽玛刀立体定向放射外科(GK-SRS)尚未被研究。本方案拟纳入80例确诊2年内、未达药物难治状态的患者,1:1随机至GK-SRS组或继续药物治疗组,允许交叉,意向性治疗分析,主要终点为2年时Barrow神经学研究所面部疼痛量表评估的满意疼痛控制比例。
要点
- 三叉神经痛药物治疗失败率超过50%,早期干预可能改善长期疼痛控制。
- 超早期GK-SRS指确诊后2年内、未达药物难治状态时进行的干预。
- 主要终点为2年时Barrow神经学研究所面部疼痛量表评估的满意疼痛控制比例。
核心结论
- 作者假设超早期GK-SRS相比持续药物治疗可获得更优的长期疼痛缓解,且治疗相关不良事件发生率更低。
- 若得到验证,超早期GK-SRS将代表三叉神经痛管理的范式转变,实现更好的长期疼痛控制且无药物相关副作用。
研究设计与样本
- 单中心、两臂、随机、对照、平行组设计、实用性、非劣效性、II期试验。
- 计划纳入80例参与者,按1:1随机分配至GK-SRS干预组或持续药物治疗对照组。
- 纳入确诊三叉神经痛2年内、尚未达到药物难治状态的患者,允许对照组交叉至干预组,采用意向性治疗分析。
主要发现
- 目前尚未报告试验结果,本文为研究方案。
- 原文指出已发表数据显示疼痛发作3年内早期干预可改善长期结局。
关键数值与推荐
- 主要结局为2年时采用Barrow神经学研究所面部疼痛量表评估的满意疼痛控制参与者比例。
- 药物治疗失败率超过50%。
- 早期干预定义为疼痛发作3年内。
- 超早期GK-SRS定义为确诊三叉神经痛2年内、药物难治状态出现前。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trigeminal neuralgia (TN) is a chronic, often debilitating neuropathic facial pain condition. First-line treatment is medical therapy, with carbamazepine (CBZ) being the gold standard. Surgery, including stereotactic radiosurgery in particular with Gamma Knife (GK-SRS), is usually considered when medical management fails, which occurs in >50% of patients. While surgery can provide long-term relief, prolonged disease duration before intervention is linked to a reduced response rate. A highly precise type of radiation therapy, GK-SRS is a non-invasive management option in TN, with a low risk of serious complications and fewer bothersome side effects compared to medical therapy. Evidence supports the safety and efficacy of GK-SRS in medically refractory TN, with published data suggesting that earlier intervention (within 3 years of pain onset) leads to improved long-term outcomes. However, the safety and efficacy of ultra-early GK-SRS-administered soon after TN diagnosis and before medical refractoriness-have not been examined. We hypothesize that ultra-early GK-SRS will yield superior long-term pain relief compared to ongoing medical management while also having a lower incidence of treatment-related adverse events (AEs). METHODS: We will perform a single-center, two-arm, randomized, controlled, parallel group design, pragmatic, noninferiority, phase II trial of ultra-early GK-SRS for TN in participants who will be treated before they have developed a medically refractory state and within 2 years of diagnosed TN per study neurologist. Eighty participants will be randomized 1:1 to either GK-SRS (intervention arm) or ongoing medical management (non-intervention/control arm). Crossover from the non-intervention/control arm to the intervention arm will be permitted. An intention-to-treat analysis will be conducted. The primary outcome will be the proportion of participants with satisfactory pain control at 2 years by the Barrow Neurological Institute Facial Pain Scale. DISCUSSION: This trial aims to test ultra-early GK-SRS as a first-line option in TN, based on a sound rationale for offering GK-SRS prior to failure of medical therapy. If validated, ultra-early GK-SRS will represent a paradigm shift in TN management leading to improved long-term pain control free from adverse medication-related side effects. TRIAL REGISTRATION: ClinicalTrials.gov NCT06949436. Registered on April 28, 2025.
引用
- Lussoso A, Patel S, Hussain W, et al. Ultra-early Gamma Knife stereotactic radiosurgery for trigeminal neuralgia (URGEnt-TN): study protocol for a single-center, two-arm, parallel group design, pragmatic, noninferiority, phase II, randomized controlled trial with intention-to-treat analysis for pre-refractory GK-SRS in classical or idiopathic TN. Trials. 2025. PMID: 41345955. doi:10.1186/s13063-025-09321-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。